Oncology & Cancer Immunology
Oncology & Cancer Immunology
Search
Financial year 2018
Financial year 2018
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Connecting our employees to nonprofits that help people around the world
Learn about the new online tool that we’re using to help our employees connect with nonprofits that are providing critical services to communities, choose volunteer activities in their field, and lend their expertise to those in need.
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Country Management Committee: A Message | Boehringer Ingelheim US
Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.
Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is fighting against foot-and-mouth disease by continuing to supply the US vaccine bank.
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Ruminants
Ruminants
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Supplier Diversity
Supplier Diversity
FDA accepts sNDA for children/adolescents with fibrosing ILD
U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.
Partnering for Innovative Pet Therapeutics
Partnering for Innovative Pet Therapeutics
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Ridgefield Research and Innovation
Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.